Patents by Inventor Cyril B. Dousson

Cyril B. Dousson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190233463
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 1, 2019
    Applicants: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: Stephane BOGEN, David DUKHAN, Guillaume BRANDT, Claire Pierra ROUVIERE, Cyril B. DOUSSON, Francois-Rene ALEXANDRE
  • Publication number: 20190192548
    Abstract: The present invention relates to methods of treating or preventing a viral infection using Compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Compound of Formula (I).
    Type: Application
    Filed: June 20, 2017
    Publication date: June 27, 2019
    Applicants: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: Stephane BOGEN, David DUKHAN, Cyril B. DOUSSON, Christophe Claude PARSY
  • Publication number: 20190183912
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 20, 2019
    Applicants: Merck Sharp & Dohme Corp., IDENIX PHARMACEUTICALS LLC
    Inventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
  • Patent number: 10238680
    Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 26, 2019
    Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan
  • Patent number: 10231986
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 19, 2019
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Christophe Claude Parsy, Gilles Gosselin, Jean-François Griffon, Guillaume Brandt, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistar James Stewart
  • Patent number: 10202411
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: February 12, 2019
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Cyril B. Dousson, Gilles Gosselin, Jean-Laurent Paparin, Guillaume Brandt, Rachid Rahali, Aurelien Salanson, François-René Alexandre
  • Publication number: 20180258130
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 13, 2018
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
  • Publication number: 20180208621
    Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
    Type: Application
    Filed: May 25, 2016
    Publication date: July 26, 2018
    Inventors: Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Chtirstophe C. Parsy
  • Patent number: 10030044
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, Z1, Z2, Z3, Z4, V, W, X, Ar, R1 and R2 are as described herein.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 24, 2018
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy
  • Patent number: 10005779
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 1?,4?-thio nucleoside compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof; wherein Base, RA, RB, W, X, Y, and Z are as described herein.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: June 26, 2018
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Gilles Gosselin, Cyril B. Dousson
  • Publication number: 20180162898
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4?-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 14, 2018
    Applicant: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, James Alistair Stewart
  • Publication number: 20180155385
    Abstract: The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
    Type: Application
    Filed: May 23, 2016
    Publication date: June 7, 2018
    Applicant: IDENIX PHARMACEUTICALS LLC
    Inventors: Cyril B. DOUSSON, David DUKHAN, Christophe Claude PARSY
  • Publication number: 20170198005
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-dichloro or 2?-fluoro-2?-chloro nucleoside analogue compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula (I): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; wherein each of RA and RB is independently Cl or F, wherein at least one of RA and RB is Cl; and Base, PD and Z are as described herein.
    Type: Application
    Filed: November 26, 2014
    Publication date: July 13, 2017
    Applicant: IDENIX PHARMACEUTICALS LLC
    Inventors: Jean-Laurent Paparin, Eric Badaroux, Claire Pierra, Cyril B. Dousson
  • Publication number: 20170044205
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 16, 2017
    Inventors: David DUKHAN, Cyril B. DOUSSON, Gilles GOSSELIN, Jean-Laurent PAPARIN, Guillaume BRANDT, Rachid RAHALI, Aurelien SALANSON, François-René ALEXANDRE
  • Publication number: 20170029456
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver cancer such as hepatocellular carcinoma, cholangiocarcinoma, or biliary tract cancer. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: (I); or a pharmaceutically acceptable salt thereof, wherein Base, Z1, Z2, Z3, Z4, V, W, X, Ar, R1 and R2 are as described herein.
    Type: Application
    Filed: November 25, 2014
    Publication date: February 2, 2017
    Applicant: IDENIX PHARMACEUTICALS LLC
    Inventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy
  • Publication number: 20160229866
    Abstract: Provided herein are hepatitis C virus inhibitor compounds, for example, of any of Formulae I to XIV, Ilia to XlVa, Illb to XlVb, IIIc to XIVc, Hid to XlVd, Ille to XlVe, IA to IAe, IIA to IIAe, IB, IIB to IIBd, IIIB to IIIBd, IC to ICc, ID to IDd, and IE to lEc.pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for treating an HCV infection.
    Type: Application
    Filed: September 19, 2014
    Publication date: August 11, 2016
    Applicant: Idenix Pharmaceuticals Inc.
    Inventors: Cyril B. Dousson, Jean-Laurent Paparin
  • Patent number: 9403863
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula I: or a pharmaceutically acceptable salt, solvate, tautomeric or polymorphic form thereof.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: August 2, 2016
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Dominique Surleraux, Cyril B. Dousson, Gilles Gosselin, David Dukhan, Claire Pierra, Jerome Peyronnet
  • Patent number: 9339541
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 17, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cyril B. Dousson, Benjamin Alexander Mayes, David Dukhan, Adel M. Moussa, Alistair James Stewart
  • Publication number: 20160113956
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.
    Type: Application
    Filed: September 25, 2015
    Publication date: April 28, 2016
    Inventors: David DUKHAN, Christophe Claude PARSY, Gilles GOSSELIN, Jean-François GRIFFON, Guillaume BRANDT, Cyril B. DOUSSON, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
  • Patent number: 9296778
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: March 29, 2016
    Assignees: Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences Et Techniques
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Gilles Gosselin, Houcine Rahali, Dominique Surleraux